දූරකථන ඉණාගෙරීධන් Telephone) 2698475) 2698490) 2698507		මගේ අංකය எனது இல My No.)
നമ്പ് പ്രേക്സ് Fax) 2692913) 2694860		ඕබේ අංකය	EPID/151/2011
විද්පුත් තැපෑල)		உமது இல Your No.	} minua .I
மின்னஞ்சல் முகவரி e-mail) postmaster@health.gov.lk)	සුවසිරිපාය	දිගය නිසනි) 02/01/2014
වෙබ් අඩවිය		சுவசிரிபாய	Date	Chick set in section
இணையத்தளம் website) www.health.gov.lk	UWASIRIPAYA		

මසෟබ්‍ය අමාත්‍යාංශය சுகாதார அமைச்சு Ministry of Health

Provincial Directors of Health Services,
Regional Directors of Health Services,
Heads/ Directors of Institutions,
Directors of National Hospital/Teaching Hospitals/Provincial & District General Hospitals,
Base Hospitals,
All Medical Superintendents of other Hospitals,
All Regional Epidemiologists/ Medical Officers (Maternal and Child Health),
All Medical Officers of Health.

Elimination of Measles/Rubella/CRS by 2018

Measles is a highly infectious disease responsible for a high degree of morbidity and mortality among children. Fatal cases of measles is now rarely reported after successful implementation of the National Immunization Programme. The measles vaccine was introduced into the Expanded Programme on Immunization (EPI) in Sri Lanka in 1984. Morbidity and mortality of measles were reduced remarkably since then. But an outbreak of measles with over 15,000 infected cases was experienced in Sri Lanka from September 1999 to June 2000. This was identified as accumulation of susceptible individuals over the years since the efficacy of measles vaccine is only 85%. The decision to introduce the 2nd dose of measles was taken based on this incident and MR vaccine (Rubella containing Measles vaccine) was introduced to all children at the age of 3 years since 2001. After 12 years, an outbreak of measles with near 4,000 suspected cases including around 1,800 laboratory confirmed, was experienced from January to December 2013.

Rubella is a mild disease affecting children and adults. It assumes considerable significance in pregnant women where it is transmitted to the foetus across the placental barrier sometimes with significant teratogenic effects. Rubella vaccine was introduced into the National EPI in 1996 targeting all reproductive aged females of 11-44 years, with the objective of preventing Congenital Rubella Syndrome (CRS). This was carried out as a school based programme by giving rubella vaccine to all children aged 11-15 years, and vaccinating the rest at the community clinics. Number of Measles and CRS cases were markedly reduced and surveillance of measles, Rubella and CRS was strengthened in 2005-2010 under the plan of 'intensification of the surveillance of Measles, Rubella, CRS' and facility of Laboratory confirmation was made available for all suspected cases of Measles, Rubella and CRS.

In 2011, MMR (Measles, Mumps, and Rubella) vaccine was introduced in 2 doses at the age of 1 year and at the age of 3 years, replacing measles (9 months) and MR (3 years).

1. Elimination Plan 2013-2018

In par with the Regional Measles, Rubella and CRS elimination strategic plans, Sri Lanka has set the goal of elimination of Measles, Rubella, CRS by 2018.

Vision: Sri Lanka to be free from Measles, Rubella and CRS

Goal: To achieve a status that Measles, Rubella and CRS are not major public health problems in Sri Lanka

Objectives: To achieve and maintain zero mortality and eliminate Measles ,Rubella/CRS in Sri Lanka

Elimination targets:

- <5 measles cases/ million population by 2015 and < 1 case per / million population by 2018
- <10 Rubella cases/ million population by 2018
- <1 CRS case/ 100,000 Live births by 2018

Components of elimination strategies:

- 1. Achieve and maintain high levels of population immunity by providing two doses of Measles and Rubella containing vaccines with high vaccination coverage.
- 2. Monitor diseases with strengthened disease surveillance including laboratory confirmation of all suspected cases of Measles, Rubella, CRS cases: case based investigation.
- 3. Strengthen Country preparedness for outbreak investigation, confirmation and response.
- 4. Adequate patient care management to prevent the transmission and mortality.
- 5. Perform research to identify evidence based support for cost effective implementation strategies for vaccination, population level seroprevalence (immunity levels), surveillance and diagnosis including laboratory confirmation.

2. Measles and Rubella vaccination

- All eligible children who have completed the age of 1 year and the age of 3 years are to be vaccinated with MMR vaccine according to the current National EPI schedule in Sri Lanka.
- Required to achieve and maintain above 95% coverage in each of the two doses of MMR vaccines at the district and national levels.
- Ensure all women in the reproductive age are protected with at least one Rubella/Rubella containing vaccine.
- Ensure that all women are protected/vaccinated for Rubella at the time the Public Health Midwife (PHM) includes them in the Eligible couple register.

• If any pregnant woman is found unvaccinated for Rubella, (and if the family has not been completed) she should be vaccinated for Rubella after delivery to prevent a future CRS case.

3. Case definitions

3.1 Surveillance case definition of Measles

Any person with: Fever and Maculopapular (i.e. non vescicular) rash and at least one of the following:

- Cough
- Coryza (i.e. runny nose)
- Conjunctivitis (i.e. red eyes)

3.2 Surveillance case definition of Rubella

Any person with: Acute onset of generalized maculopapular rash; temperature above 99.0°F. (above 37.2°C); arthralgia, arthritis, lymphadenopathy (usually suboccipital/postauricular/cervical) or conjunctivitis.

3.3 Surveillance case definition of CRS

Any infant with: Maternal history of Rubella infection and / or with signs and symptoms from following categories

 cataract, congenital glaucoma, pigmentary retinopathy, Congenital heart disease (PDA/peripheral pulmonary artery stenosis/VSD), Loss of hearing

 Purpura, splenomegaly, microcephaly, mental retardation, Meningoencephalitis, Radiolucent bone disease, jaundice (within 24 hours of delivery)

or

Laboratory data consistent with Congenital Rubella Infection (Rubella IgM positive or Rubella virus isolated)

4. Measles/Rubella/CRS case reporting

National Measles/Rubella and CRS registers are maintained at the Epidemiological Unit.

It has been decided to consider all AFP surveillance sentinel sites as Measles/Rubella/CRS surveillance sites. These sentinel site health care institutions are the hospitals where a paediatrician and/or physician are available.

- All suspected Measles and Rubella patients should be notified to the Epidemiology Unit through the new format 'Suspected Measles / Rubella Patient Information Form' (EPID/151/1/2013, Blue Form) [Annexure 1] filled by the Clinician/Medical Officer who is treating the patient at first patient contact.
- The routine notification has to be sent to the Medical Officer of Health (MOH) of the patient's residential area (Notification of Communicable Diseases: Health-544) for all <u>suspected cases</u> of Measles, Rubella, CRS by the Clinician who is treating the patient.
- All suspected CRS cases need to be reported to the Epidemiology Unit immediately by phone/fax/E-mail and special investigation form (EPID/DS/CRS/2013) [Annexure 2] is required to be properly completed by the Clinician/Medical Officer who is treating the patient at the health institution and sent to the Epidemiology Unit.

- All infection control nursing officers (ICNO) at the sentinel site hospitals are
 expected to maintain a Measles/Rubella and CRS registers (Format: Annexure 3
 and 4). The infection control nurses are also expected to visit medical, paediatric,
 obstetric, cardiology, ophthalmology and ENT wards regularly for detection of cases
 (all Measles, Rubella, CRS) and to notify promptly to the Epidemiology Unit.
- All suspected cases of Measles, Rubella/CRS presented to sentinel site hospitals should be included in the Weekly reporting form for AFP, Measles, Rubella cases from hospital (sentinel sites) EPID/37/5/R2004 (Annexure 5), and should be sent on every Friday to the Chief Epidemiologist, Epidemiology Unit, Colombo with copy to the Regional Epidemiologist. This form should be sent even if no cases have been detected (nil reporting) for the week. A total of 52 reports should be received from each site per year and the timeliness of the return needs to be maintained at 7 days to be received at the Epidemiology Unit. The performance rate of completeness of timeliness of the return will be measured.
- The patients identified in other health institutions other than sentinel sites, or by a General Practitioner, are required to be promptly notified to the relevant MOH (Notification of Communicable Disease, [Health 544] form or any other means of notification) and the laboratory confirmation should be carried out as instructed.
- The MOH has to proceed with routine surveillance procedure for all notified or community detected Measles, Rubella, CRS cases and complete the special field investigation form for clinical confirmation, contact tracing and outbreak prevention.
- All clinically confirmed cases of Measles, Rubella and CRS need to be completed with special investigation forms by the MOH ([EPID/DS/MEASLES/2007] , [EPID/DS/RUBELLA.2007], [EPID/DS/CRS/2013])_(Annexure 6, 7 & 2) and duly completed forms should be sent to the Epidemiology unit as early as possible.
- If the notified Measles/Rubella case has not been laboratory confirmed due to any reason by the Health Institution, the MOH should perform the laboratory confirmation at the time of special field investigation as per the Epidemiology Unit letter No: EPID/151/2011 dated 20/09/2012.
- All Measles/Rubella cases detected at the community level by any of the public health staff, need to be adequately investigated, in accordance with the routine surveillance and special investigation procedure, with laboratory confirmation to complete case based investigation by the MOH.

6. Laboratory investigations for suspected Measles/Rubella and CRS cases

- A blood sample of 2-3ml for Measles /Rubella IgM should be collected from each suspected case of Measles, or Rubella from the 3rd day to 28th day of the onset of signs and symptoms, into a sterile, dry, screw capped container without any anti coagulant.
- A blood sample for Rubella IgM (or for TORCH screen as for Toxoplasma, Rubella, Cytomegalovirus, Herpes simplex virus in screening for congenital abnormalities) should be taken from all suspected infants of CRS and from newborns in instances where the mother has declared a history of suspected/confirmed Rubella infection in any gestational age of pregnancy.

- If any pregnant woman who does not give a history of Rubella vaccination is identified in any Obstetric Unit, she is required to be tested for Rubella IgM to identify recent possible Rubella infection during gestational period. In case a positive result is obtained, the baby is required to be investigated on delivery and followed up for possible CRS.
- Once the blood sample has been collected, it should be labeled and left at room temperature for about 30 minutes and send to the laboratory in a cold box as soon as possible.
- If facilities to centrifuge is available, properly labelled separated serum should be sent to the Virology laboratory, MRI for Measles or Rubella IgM detection.
- The sample should be received at the laboratory within 48 hours of collection for adequate antibody detection and if there is any delay of transport more than 6 hours the sample should be refrigerated until dispatch to prevent destruction of antibodies.
- The sample should be sent to Measles/Rubella Virology Laboratory at the Medical Research Institute for IgM antibodies for confirmation of the diagnosis with the MRI request form with adequate information.
- Naso-pharyngeal aspirates, throat and/or nasal swabs or gingival swabs for Measles/Rubella virus or antigen detection can be done within the first 5 days of the onset of symptoms and samples should be transported to the laboratory in virus transport media, properly labelled, with a request form, in a cold box with ice.

Please bring the contents of this circular to the notice of all relevant staff at your institution/district/province and arrange to implement the programme accordingly.

Dr. P. G. Mahipala

Director General of Health Services

Ministry of Health

Copy:

- Secretary Health
- DDG/PHS 1
- DDG/PHS 11
- DDG/MS
- Chief Epidemiologist

EPIDEMIOLOGY UNIT – MINISTRY OF HEALTH Measles / Rubella Elimination Initiative Suspected Measles / Rubella Patient Information

Measies / Mudella El	HOHOGERON HUNCHAUSE
Suspected Measles / Rub	ella Patient Information
	For Office use only
20 -	Adap / Pub ID Codo CDI / TO / TO / TO /

Please Mark		7	For Office use on	ly		
Measles Rube	lla 🗍		Mea/Rub ID Cod	e SRL/]/00/0	
			on suspicion of the diagnos ail: <u>chepid@sltnet.lk,</u> <u>epidu</u>			
Name of Hospital						
Inward patient V	Vard No.	BHT No.	Date of Admission	OPD pat	ient /	OPD No
Yes No				Yes	No	
Particulars of the Pa	tient					
Name		**********				***************************************
Address		***********	*******************************			**************
		***********	*****************************			*************
Telephone N	lo. :-	***********	***************************************	**************	5# 88 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	***************************************
MOH Area		**********		**************	*************	************
District		V	Month	Data		**************
Date of Birth		Year		Date		
Age		Male	Female 🗍 -			
Sex		Male []	remale []			
linical History						
Date of onse	t of fever :	Year 🗌	OO Month	Date		
Date of onset	of rash :-	Year 🔲	Month	Date	00	
Cough						
Coryza						
Conjunctivitis			,			
Lymphadenor		(sub occipital)	/ post auricular / cervica	")		
Other (specify		1,1,11,11,11,11,11,11,11,11,11,11,11,11				
ecimen collection		Serology	☐ Virus Isolation			
ecimen details						
ite of collection of blo	ood Date of d	ispatch to	Date of collection of sa	wabs	Date of	dispatch to
M)	MRI		(Nasal/Throat swabs f Virus Isolation)	ог	MRI	
	The state of the s					47125 217022 445252
Name of the medic	cal officer			Desig	gnation	

SURVEILLANCE OF CONGENITAL RUBELLA SYNDROME (CRS) - CASE INVESTIGATION FORM EPIDEMIOLOGY UNIT, MINISTRY OF HEALTH

The Medical Officer/Hospital and REE/MOH should carry out the investigation personally. Necessary data should be obtained from the mother of the new baby/BHT/Physician/investigation reports/diagnosis cards. Early investigation and return is essential.

		Serial No:		
A. GENERAL 1. Date of notification to MOH: 2. Date of notification to Epidemiology 3. Name of the reporting Institution / Ho 4. Ward No: 5. BHT No: 6. Name of the hospital where the baby 7. Ward No: 8. BHT No:	Unit:] (dd/mm/yy)		
9. Name of patient (BLOCK LETTERS 10. Name of the parent/guardian	(dd/mm/yy) 15. Ethnic group 1. Sinhalese 2. Tamil 3. Moor 17. E	Mother's occupation		
B. PRESENT ILLNESS /OUTCOM 19. Date of detection of signs and symptoms of CRS: d d mm y y 20. Where did the patient detect first 1. Government hospital 2. Private hospital 3. Medical Officer of Health 4. Private practitioner 5. Ayurvedic institution 6. Other (specify)	21. Outcome of the event 1. Still under treatment 2. Died 3. Transferred 4. Discharged 22. Date of discharge, transfer (where relevant) d d m m y y	r or death	24. Was patie other hosp Yes 🔲 / N	No here was the patient
C. CLINICAL DATA Surveillance Case definition: Child <1 year of age with maternal hist List A 1. Cateract/s 2. Congenital glaucoma 3. Congenital hearth disease 4. Loss of hearing 5. Pigmentary Retinopathy	List B 1. Purpura 2. Splenomegaly 3. Microcephaly 4. Mental Retardation 5. Meningo-encephalitis 6. Radiolucent bone disease 7. Jaundice (within 24hr of delivery)	Laboratory data with Congenital Finfection (CRI) positive resurbella IgM	consistent Rubella	For office use only Compatible with the case definition. 1. Yes 2. No

Date of collection of specimen (dd/mm/yy)	Laboratory MRI/ other govt./ p		Results (mark NA if t
specimen	MRI/ other govt./ p		Paculta (mark NA if t
7,7	not known	private/	results are not availal and RP if pending)
	1000 214-1		
	THE PARTY		
		060018	
E MOTHERIS HAMINIZATI	ON HISTORY C	CONTAC	T LIETODY
			ed case of rubella during
not known		3. not	known
36. Type of vaccine used:	4	0. If yes, perio	od of gestation in weeks:
1. Rubella 3. MR 2. MMR 4. Not kn	own		
37. Place of vaccination		not kn	nown
1. MOH clinic	and an arrange of the		
3. government hospital 4. private dispensary/surg	ery		
6. other (specify)			
7. not known			
38. If not immunized, reason:			
2. unaware of the need fo	rvaccination		
4. no faith in the vaccine	ne	The state of the s	DR OFFICE USE
5. otners (specify)			ween immunization and ent of maternal infection
6. not known			yrs months
	34. Was the mother immunized for	34. Was the mother immunized for rubella? 1. yes 2. no 3. not known 35. If yes, date of vaccination: d d m m y y not known 36. Type of vaccine used: 1. Rubella 3. MR 2. MMR 4. Not known 37. Place of vaccination 1. MOH clinic 2. school 3. government hospital 4. private dispensary/surgery 5. private hospital 6. other (specify) 7. not known 38. If not immunized, reason: 1. medical contraindication 2. unaware of the need for vaccination 3. non-availability of vaccine 4. no faith in the vaccine 5. others (specify)	34. Was the mother immunized for rubella? 1. yes 2. no 3. not known 35. If yes, date of vaccination: 1. yes 1. yes 2. no 3. not known 36. Type of vaccine used: 1. Rubella 3. MR 2. MMR 4. Not known 37. Place of vaccination 1. MOH clinic 2. school 3. government hospital 4. private dispensary/surgery 5. private hospital 6. other (specify) 7. not known 38. If not immunized, reason: 1. medical contraindication 2. unaware of the need for vaccination 3. non-availability of vaccine 4. no faith in the vaccine 5. others (specify)

Epidemiology Unit

2013

Measles / Rubella Register Format

		_		_	 1	-	 	 ,	
Specimen collection for confirmation date & result)	noitelosi suriV sdews			7					
Specimen collection for confirmation (date & result)	Mgl 101 boold								
Date of notification	tinU biq3 oT (Etos/1/121/al93)								
Date of n	HOM oT (442 H)		,						
	Residential								
ţəsud	Date of o								
noissin	ibs to stsO						0		
	ВНТ								
	Ward								
	Sex								
	DOB								K
Name of	the								
	Disease								
	JN Isira? un IsunnA)								

Epidemiology Unit

CRS Register Format

			4						
ollection nation esult)	noitalosi auriV adswa	-				, at			
Specimen collection for confirmation (date & result)	Mgl 101 bool8								
ion	To Epid Unit (EPID/DS/CRS/2013)			92					
Date of notification	HOM oT (442 H)								
	Residential								
	Mother's vacci status Rubella								
noito	Date of dete							2	
noiss	imbs to stad								
	BHT								
	Ward/ Unit								
	Sex								
Age	detection of CRS & & DOB								,-
Name of the	Patient & Name of the mother			**					
	muM Isir92 dmun IsunnA)								

FORM: EPID/37/5/R2004

WEEKLY REPORTING FORM FOR AFP*, MEASLES, RUBELLA /CRS CASES FROM HOSPITALS

(SENTINEL SITES)

isease	Name of the patient	Age	Sex	Ward	B.H.T. No.	D:O.A	Date of onset	Residential address
						estigitine referet some virigities untir mond		
eggenerer de grap de servid e grap d					der für von die Stern von verlage de Stern der Stern von der Stern von der Stern von der Stern von der Stern v	www.cc.undowschipmadduggwagdan		
nis form nediatric is return ppy to R	e EYE, ENT a	mpleted and neur y to Epic emiologi	for all cology we demiologist, Tel:	ards dur gist, Epic 2695112	ing the we demiologic , 2681548	ek. Even cal Unit, , Fax: 26	f no cases 231, de Sa 96583, E-n	ELLA/CRS, after visiting medical have been detected, please forward ram Place, Colombo 01000 with a nail:epidunit@sltnet.lk/officer. FORM: EPID/37/5/R2
uis form nediatric is return py to Ri nepid@s	should be con EYE, ENT a every Frida egional Epida itnet.lk by He	mpleted and neur to Epi emiologi and of th	for all cology we demiologist, Tel: ne institu	ards duri gist, Epic 2695112 ution/IC	ing the we demiologic, 2681548 N/PHI or	ek. Even i cal Unit, i, Fax: 26 any other FP*, ME	f no cases 231, de Sa 96583, E-n Identified ASLES, I	have been detected, please forward ram Place, Colombo 01000 with a nail:epidunit@sltnet.lk/ officer.
his form nediatric is return ppy to Ri nepid@s	should be con EYE, ENT a every Frida egional Epida linet.lk by He WEEKLY I	mpleted and neur to Epi emiologi and of th	for all cology wedemiologist, Tel: se institu	ards durigist, Epid 2695112 ation/ICI	FOR AI HOSP (SENTIN	ek. Even cal Unit, i, Fax: 26 any other FP*, ME TTALS EL SITES	f no cases 231, de Sa 96583, E-n Identified ASLES, I	have been detected, please forward ram Place, Colombo 01000 with a nail:epidunit@sltnet.lk/ officer. FORM: EPID/37/5/R2
his form nediatric is return ppy to Ri nepid@s	should be con EYE, ENT and every Fridate egional Epidatenet.lk by He	mpleted and neur to Epi emiologi and of th	for all cology wedemiologist, Tel: se institu	ards durigist, Epid 2695112 ation/ICI	FOR AI HOSP (SENTIN	ek. Even i cal Unit, i, Fax: 26 any other FP*, ME	f no cases 231, de Sa 96583, E-n Identified ASLES, I	have been detected, please forward ram Place, Colombo 01000 with a nail:epidunit@slinet.lk / officer. FORM: EPID/37/5/R2
stitution of the control of the cont	should be con EYE, ENT and every Friday egional Epida itnet.lk by He WEEKLY I ON: reporting: (S Name of the	mpleted and neur to Epic emiologicad of the REPOF	for all cology wedemiologist, Tel: te institu	ards durigist, Epic 2695112 stion/IC/	FOR AI HOSP (SENTIN	ek. Even cal Unit, i, Fax: 26 any other FP*, ME ITALS EL SITES	f no cases 231, de Sa 96583, E-n Identified ASLES, I	have been detected, please forward ram Place, Colombo 01000 with a nail:epidunit@sltnet.lk / officer. FORM: EPID/37/5/R2 RUBELLA/CRS CASES FRO
stitution of the control of the cont	should be con EYE, ENT and every Friday egional Epida itnet.lk by He WEEKLY I ON: reporting: (S Name of the	mpleted and neur to Epic emiologicad of the REPOF	for all cology wedemiologist, Tel: te institu	ards durigist, Epic 2695112 stion/IC/	FOR AI HOSP (SENTIN	ek. Even cal Unit, i, Fax: 26 any other FP*, ME ITALS EL SITES	f no cases 231, de Sa 96583, E-n Identified ASLES, I	have been detected, please forward ram Place, Colombo 01000 with a nail:epidunit@sltnet.lk / officer. FORM: EPID/37/5/R2 RUBELLA/CRS CASES FRO

This form should be completed for all cases of AFP, MEASLES, and RUBELLA/CRS after visiting medical, paediatric EYE, ENT, and neurology wards during the week. Even if no cases have been detected, please forward this return every Friday to Epidemiologist, Epidemiological Unit, 231, de Saram Place, Colombo 01000 with a copy to Regional Epidemiologist, Tel: 2695112, 2681548, Fax: 2696583, E-mail: chepid@sltnet.lk by Head of the institution/ICN/PHI or any other identified officer.

SURVEILLANCE OF MEASLES - CASE INVESTIGATION FORM EPIDEMIOLOGY UNIT, MINISTRY OF HEALTH The MOH should do the investigation personally. Necessary data should be obtained from the hospital by reference to the BHT/ Physician or from the diagnosis card. Early investigation and return are essential. Week ending Please write the Serial No given in the Infectious of notification Serial no: Disease Register (ID Register) in the MOH office d d m m A. PARTICULARS OF PATIENT (Please tick (3) the appropriate box where applicable) Name of patient (BLOCK LETTERS) 2. Residential address: 3. Date of birth: (dd/mm/yyyy) 4. Age 5. Sex 6. Ethnic group 7. Occupation 8. DPDHS division (district) 9. MOH area 1. male 1. Sinhalese 2. female 2. Tamil y/mm 3. not known 3. Moor FOR OFFICE USE ONLY 4. others 5. not known **B. PRESENT ILLNESS/OUTCOME** 10. Date of onset of symptoms: 12. Was patient admitted to hospital? 17. Date of discharge/transfer or death: 1. yes to Q. 13 d m skip 18. If transferred, name of hospital 11. Where did the patient first seek to Q. 21 3. not known medical advice? 13. If yes, date of admission: 19. Was patient transferred from some other 1. government hospital hospital? 2. private hospital 2. no 1. yes 3. private practitioner 14. Name of hospital: 20. If "yes", where was the patient transferred from? 4. Ayurvedic institution (public/private) 21. Outcome of the case 15. Ward: 5. other (specify) 1. cured 3. transferred 16. BHT no: 2. died 4. not known C. CLINICAL DATA Case definition: any person with fever with maculopapular rash (>3 days) and cough, coryza (runny nose) or conjunctivitis 22. Symptoms and signs 23. Complications 1. fever 1. none 2. generalized rash For office use only 2. diarrhoea Compatible with the 3. cough 3. pneumonia case definition: 4. coryza 4. otitis media ... 1. Yes 5. conjunctivitis 5. encephalitis . 2. No 6. other (specify): 6. other (specify): D. LABORATORY FINDINGS 24. Was blood taken for measles serology?

1. yes ☐ 2. no. 3. not known 25. If yes: Date of collection of Laboratory Investigation Results (mark NA if test results are not specimen (dd/mm/yy) (MRI/govt./private) available and PP if pending)

IgG 1st specimen
 IgG 2nd specimen

3. IgM

	Dose	Date of immunizatio	n* Ty	pe of va	ccine** Batch	Pla	ice of immu	nizatio	ng skrakeske
	st dose	(dd/mm/yy)			numb			111111111111111111111111111111111111111	porture ton to
	dose dose	oft (all) red Land care and					10 10		
_	ther								
								h brokk	a lo paid
	Measles 1	s not known but the particula raccine/ MR vaccine/ MMR vaccine/ MMR vaccine/ MPR vaccine/ MPR vaccine/ MPR vaccine/ MPR field of	accine/ not k	nown					
CONTAC	T HIST	RY							
		n in contact with anyone v	with fever a	and/or ra	ash within 3 weeks	s prior to ons	set of illnes	§?	
1. yes	☐ 2. r	The state of the s							
		1 – 3 with details)							
Details of in the pat	the patie	nt's household or other clo their immunization status	ose contac	ts who	developed a simila	r illness foilo	wing the de	velopm	ent of meas
Adda Market State (Market State)	Control Control		(1111 1/100/ 4	- / WILI	Date of onset	Dalational	· Vac	cinator	for measle
		Name	Age	Sex	of rash	Relationsh to patien	110	no	not know
Ba. contacts w	ith a 1			- o or			,,,,	110	TICE KITOW
ior to onset o		DOMESTIC DESCRIPTION OF THE PERSON OF THE PE			r da s				
ness in the pa	3	to occupation assessment		LO of	- magniford	1 190	70 JAP 10	1209	
a. contacts o	the 4			250	relimbs to sidely e				
itient who eveloped simil ness after the	ar 5	THE RESERVE OF THE PARTY OF THE					Tona Control		hrs. 35.7
evelopment of easles in the	6	HISTORY WITH THE			Test con to the second to the	inter the			
tient	7	Attento madur funt it is							
							10/3		(d)
					9 mm	H8 21			
Remarks:									
Remarks:									
Remarks:			•••••					***********	
Remarks:	bondig								
Remarks:	hone a								
Remarks:	bondia								evel / <u>C</u> l.
Remarks:	bonnia			official					
			- ca	olingip alignans					sa only
Remarks:			Nan	ne:				office u	se only

E. MEASLES VACCINATION STATUS

SURVEILLANCE OF RUBELLA - CASE INVESTIGATION FORM EPIDEMIOLOGY UNIT, MINISTRY OF HEALTH

The MOH should do the investigation personally. Necessary data should be obtained from the hospital by reference to the BHT / Physician or from the diagnosis card. Early investigation and return are essential.

Week ending of notification d d m m	Serial Serial	no:	Please write the Serial No give Disease Register (ID Register	en in the Infectious) in the MOH office
A. PARTICULARS OF PATIENT	(Please tick (✓)	the appropriate bo	ox where applicable)	
1. Name of patient (BLOCK LETTERS)			The state of the state of
2. Residential address:				
3. Date of birth: /		d/mm/yyyy)		
4. Age 5. Sex	6. Ethnic group	7. Occupation	8. DPDHS division (district)	9. MOH area
1. male	1. Sinhalese		mention & Ed. on	Company of the company
y y / m m 2. female 3. not known	☐2. Tamil ☐3. Moor			
3. Hot known	4. others		FOR OFFICE USE ONLY	
	☐5. not known			
B. PRESENT ILLNESS/OUTCOM	IE .			
10. Date of onset of symptoms:	12. Was patient ad	dmitted to hospital?	17. Date of discharge/transfer	or death:
	1. yes	→ to Q. 13		
d d m m y y	2. no	₹ skip	d d m m y	у
11. Where did the patient first seek	3. not know	[to 0 21]	18. If transferred, name of hos	spital
medical advice?	13. If yes, date of a	admission:	19. Was patient transferred from	
1. government hospital			hospital?	
2. private hospital	d d m	m y y	1. yes 2. no	
3. private practitioner	14. Name of hospi	tal:	20. If "yes", where was the part	tient transferred from?
4. Ayurvedic institution (public/private)				
5. other (specify)	15. Ward:		21. Outcome of the case	Statement of the second
3. Other (specify)	16. BHT no:		1. cured 3. trans	ferred
			2. died 4. not kr	nown
C. CLINICAL DATA				
Case definition: An illness with general	alized macular papu	ılar rash, fever and art	hralgia/arthritis, lymphadenopat	thy or conjunctivitis
22. Symptoms and signs		23. Compli	ications	
1. fever		□ 1. 6	encephalitis	
2. rash		□ 2. 0	other (specify):	
3. lymphadenopathy				For office use only
4. conjunctivitis				Compatible with the case definition:
5. arthritis/arthralgia				1. Yes
a state (opoury).				2. No

5. If yes	,				
Inve	estigation	Date of collection of specimen (dd/mm/yy)	Laborate (MRI/ other gov not know	t./ private/	Results (mark NA if test results are available and PP if pending)
1. lgG 1	st specimen				
2. IgG 2	2 nd specimen				
B. IgM					Harrist Policy of Street, Stre
. Virus	isolation				
. RUB	ELLA VACC	INATION STATUS			
3. Was	rubella/MMR/	MR vaccine given before the o	onset of the present illne	ess?	
	yes 2. n				
7. If yes	s, details of im	munization:			THE RESERVE TO BE ASSESSED.
	Dose	Date of immunization* (dd/mm/yy)	Type of vaccine**	Batch number	Place of immunization***
	1 st dose				
	2 nd dose				
	Other			- out of the	
	** Rubella v	is not known but the particular do: /accine/ MR vaccine/ MMR vaccin fice/ Govt. hospital/ PHM field clini	e/ not known		
□ 1.	medical control	aindication 2. unaware of vaccine 5. not known	the need for vaccination		ability of the vaccine ecify)
☐ 1. ☐ 4. . CON 9. Was ☐ 1.	TACT HISTO the patient in o	ORY contact with a suspected / known 3. not known	vn case of rubella (fever	6. other (spe	
14 CON 9. Was1.	no faith in the TACT HIST(the patient in c yes	ORY contact with a suspected / known 0 3. not known Compared to the contact with a suspected for th	vn case of rubella (fever	6. other (special and rash) in the matter age only)	ecify)
☐ 1. ☐ 4. . CON 9. Was ☐ 1.	no faith in the TACT HIST(the patient in c yes	ORY contact with a suspected / known 3. not known	vn case of rubella (fever	6. other (spe	ecify)
1. 4. CON 9. Was 1. C. EXF	TACT HISTO the patient in or yes 2. n POSURE DU the patient pr	ORY contact with a suspected / known 0 3. not known Compared to the contact with a suspected for th	vn case of rubella (fever	6. other (special and rash) in the matter age only)	ecify)
1. CON 9. Was 1. If yes	TACT HISTO the patient in or yes 2. n POSURE DU the patient pross, period of generation.	DRY contact with a suspected / known 3. not known RING PREGNANCY (for egnant at the time of illness? [station in weeks:	vn case of rubella (fever females of reprodu ☐ 1. yes ☐ 2. no	☐ 6. other (special and rash) in the management of the ctive age only) ☐ 3. not known	nonth prior to the onset of rash?
1. CON 9. Was 1. EXF 0. Was 1. If yes	TACT HISTO the patient in order yes 2. n POSURE DU the patient properties, period of generates ant:	DRY contact with a suspected / known 3. not known RING PREGNANCY (for egnant at the time of illness? [station in weeks:	ryn case of rubella (fever	☐ 6. other (special and rash) in the management of the ctive age only) ☐ 3. not known	ecify)
1. CON 9. Was 1. If yes 1. If yes 1. If preg	the patient in converse 2. no faith in the patient in converse 2. no possible patient process, period of generat: nant mothers se investigation.	DRY contact with a suspected / known 3. not known RING PREGNANCY (for egnant at the time of illness? [station in weeks:	ryn case of rubella (fever	☐ 6. other (special and rash) in the management of the ctive age only) ☐ 3. not known	nonth prior to the onset of rash?
1. CON 9. Was 1. If yes mporta	the patient in converse 2. no faith in the patient in converse 2. no possible patient process, period of generat: nant mothers se investigation.	DRY contact with a suspected / known 3. not known RING PREGNANCY (for egnant at the time of illness? [station in weeks:	ryn case of rubella (fever	☐ 6. other (special and rash) in the management of the ctive age only) ☐ 3. not known	nonth prior to the onset of rash?
1. CON 9. Was 1. If yes mporta	the patient in converse 2. no faith in the patient in converse 2. no possible patient process, period of generat: nant mothers se investigation.	DRY contact with a suspected / known 3. not known RING PREGNANCY (for egnant at the time of illness? [station in weeks:	ryn case of rubella (fever	☐ 6. other (special and rash) in the management of the ctive age only) ☐ 3. not known	nonth prior to the onset of rash?
1. CON 9. Was 1. If yes nporta	the patient in converse 2. no faith in the patient in converse 2. no possible patient process, period of generat: nant mothers se investigation.	DRY contact with a suspected / known 3. not known RING PREGNANCY (for egnant at the time of illness? [station in weeks:	ryn case of rubella (fever	☐ 6. other (special and rash) in the management of the ctive age only) ☐ 3. not known	nonth prior to the onset of rash?
1. CON 9. Was 1. If yes nporta	the patient in converse 2. no faith in the patient in converse 2. no possible patient process, period of generat: nant mothers se investigation.	DRY contact with a suspected / known 3. not known RING PREGNANCY (for egnant at the time of illness? [station in weeks:	ryn case of rubella (fever	☐ 6. other (special and rash) in the management of the ctive age only) ☐ 3. not known	nonth prior to the onset of rash?
1. CON 9. Was 1. If yes 1. If yes 1. If preg	the patient in converse 2. no faith in the patient in converse 2. no possible patient process, period of generat: nant mothers se investigation.	DRY contact with a suspected / known 3. not known RING PREGNANCY (for egnant at the time of illness? [station in weeks:	ryn case of rubella (fever	☐ 6. other (special and rash) in the management of the ctive age only) ☐ 3. not known	nonth prior to the onset of rash?
1. CON 9. Was 1. If yes mporta II preg	no faith in the TACT HISTO the patient in or yes	DRY contact with a suspected / known 3. not known RING PREGNANCY (for egnant at the time of illness? [station in weeks:	females of reproduction of the followed up.	☐ 6. other (special and rash) in the management of the baby is found in the baby in the baby is found in the baby	nonth prior to the onset of rash? Indicate to have acquired CRS, a separate of the control of t
1. CON 9. Was 1. If yes mporta II preg	no faith in the TACT HISTO the patient in or yes	DRY contact with a suspected / known 3. not known RING PREGNANCY (for egnant at the time of illness? [station in weeks:	females of reproduction of the followed up. 1007 must be filled.	☐ 6. other (special and rash) in the management of the baby is found in the management of the baby is found in th	For office use only Final classification
4. 9. Was 1. 6. EXF 30. Was 1. If yes	no faith in the TACT HISTO the patient in or yes	DRY contact with a suspected / known 3. not known RING PREGNANCY (for egnant at the time of illness? [station in weeks:	females of reproduction of the followed up.	☐ 6. other (special and rash) in the management of the baby is found in the management of the baby is found in th	For office use only Final classification